Curtis Cooper

17.5k total citations · 2 hit papers
356 papers, 9.2k citations indexed

About

Curtis Cooper is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Curtis Cooper has authored 356 papers receiving a total of 9.2k indexed citations (citations by other indexed papers that have themselves been cited), including 224 papers in Epidemiology, 198 papers in Hepatology and 155 papers in Infectious Diseases. Recurrent topics in Curtis Cooper's work include Hepatitis C virus research (192 papers), Liver Disease Diagnosis and Treatment (113 papers) and Hepatitis B Virus Studies (96 papers). Curtis Cooper is often cited by papers focused on Hepatitis C virus research (192 papers), Liver Disease Diagnosis and Treatment (113 papers) and Hepatitis B Virus Studies (96 papers). Curtis Cooper collaborates with scholars based in Canada, United States and United Kingdom. Curtis Cooper's co-authors include Edward J. Mills, D. William Cameron, Jean B. Nachega, Marina B. Klein, Beth Rachlis, Kumanan Wilson, Sonal Singh, Iain Buchan, David R. Bangsberg and Robert S. Hogg and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Curtis Cooper

334 papers receiving 8.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adherence to Antiretroviral Therapy in Sub-Saharan Africa and North America

2006 704 citations Edward J. Mills, Curtis Cooper et al. profile →
Adherence to HAART: A Systematic Review of Developed and Developing Nation Patient-Reported Barriers and Facilitators

2006 624 citations Edward J. Mills, Curtis Cooper et al. profile →

Peers

Countries citing papers authored by Curtis Cooper

Since Specialization

Citations

This map shows the geographic impact of Curtis Cooper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Curtis Cooper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Curtis Cooper more than expected).

Fields of papers citing papers by Curtis Cooper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Curtis Cooper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Curtis Cooper. The network helps show where Curtis Cooper may publish in the future.

Co-authorship network of co-authors of Curtis Cooper

This figure shows the co-authorship network connecting the top 25 collaborators of Curtis Cooper. A scholar is included among the top collaborators of Curtis Cooper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Curtis Cooper. Curtis Cooper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Autoantibodies targeting angiotensin‐converting enzyme 2 are prevalent and not induced by SARS ‐ CoV ‐2 infection 2025 ·The FASEB Journal ·Yannick Galipeau, (unknown), (unknown), (unknown), (unknown), (unknown), Corey Arnold, Martin Pelchat, Kevin D. Burns, Curtis Cooper, Marc‐André Langlois	0
2	Association of MASLD Phenotypes With Liver Fibrosis in Hepatitis C: The Role of Cardiometabolic Risk Factors 2025 ·Journal of Viral Hepatitis ·(unknown), (unknown), Shlomo Sasson, Agnihotram V. Ramanakumar, (unknown), (unknown), Marc Deschênes, Phil Wong, Tianyan Chen, Nadine Kronfli, Sahar Saeed, (unknown), (unknown), Curtis Cooper, Giada Sebastiani	3
3	Canadian health care providers' and education workers' hesitance to receive original and bivalent COVID-19 vaccines 2024 ·Vaccine ·Brenda L. Coleman, Iris Gutmanis, Susan J. Bondy, (unknown), Joanne M. Langley, (unknown), Curtis Cooper, Louis Valiquette, Matthew Muller, Jeff Powis, Dawn M. E. Bowdish, Kevin Katz, Mark Loeb, Marek Smieja, Shelly McNeil, Samira Mubareka, Jeya Nadarajah, (unknown), Allison McGeer	4
4	Obesity does not influence SARS-CoV-2 humoral vaccine immunogenicity 2024 ·npj Vaccines ·(unknown), (unknown), Christopher A. Gravel, Marc‐André Langlois, Curtis Cooper	4
5	Reduced seasonal coronavirus incidence in high‐risk population groups during the COVID‐19 pandemic 2024 ·Immunity Inflammation and Disease ·(unknown), Yannick Galipeau, Julian Little, Marc‐André Langlois, Curtis Cooper	2
6	Frequent Disengagement and Subsequent Mortality Among People With HIV and Hepatitis C in Canada: A Prospective Cohort Study 2024 ·Open Forum Infectious Diseases ·Sahar Saeed, (unknown), (unknown), Erica E. M. Moodie, Joseph Cox, Curtis Cooper, M. John Gill, Valérie Martel‐Laferrière, Dimitra Panagiotoglou, Sharon Walmsley, Alexander Wong, Marina B. Klein	3
7	Role of fatty liver in the epidemic of advanced chronic liver disease among people with HIV: protocol for the Canadian LIVEHIV multicentre prospective cohort 2023 ·BMJ Open ·(unknown), Sahar Saeed, (unknown), (unknown), (unknown), Erica E. M. Moodie, Colleen Price, (unknown), Curtis Cooper, Sharon Walmsley, Neora Pick, Melanie C. M. Murray, Joseph Cox, Nadine Kronfli, Cecilia T. Costiniuk, Alexandra de Pokomandy, Jean‐Pierre Routy, Bertrand Lebouché, Marina B. Klein, Giada Sebastiani	4
8	COVID‐19 vaccine effectiveness by HIV status and history of injection drug use: a test‐negative analysis 2023 ·Journal of the International AIDS Society ·Joseph H. Puyat, James Wilton, (unknown), Naveed Z. Janjua, Jason Wong, Troy Grennan, Catharine Chambers, Abigail Kroch, Cecilia T. Costiniuk, Curtis Cooper, (unknown), (unknown), Ann N. Burchell, Aslam H. Anis, Hasina Samji, (unknown)	1
9	Seasonal respiratory virus circulation was diminished during the COVID‐19 pandemic 2022 ·Influenza and Other Respiratory Viruses ·(unknown), Yannick Galipeau, Julian Little, (unknown), K. Ramotar, Marc‐André Langlois, Curtis Cooper	17
10	Effectiveness of COVID-19 vaccines in people living with HIV in British Columbia and comparisons with a matched HIV-negative cohort: a test-negative design 2022 ·International Journal of Infectious Diseases ·(unknown), Hasina Samji, Joseph H. Puyat, Naveed Z. Janjua, James Wilton, Jason Wong, Troy Grennan, Catharine Chambers, Abigail Kroch, Cecilia T. Costiniuk, Curtis Cooper, Ann N. Burchell, Aslam H. Anis	9
11	Hepatitis C virus testing in a clinical HIV cohort in Ontario, Canada, 2000 to 2015 2021 ·Health Science Reports ·(unknown), Ramandip Grewal, Tony Mazzulli, Curtis Cooper, Sandra Gardner, Irving E. Salit, Abigail Kroch, Ann N. Burchell, (unknown)	3
12	Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real‐World Study 2021 ·Journal of Viral Hepatitis ·Mina Farag, Scott Fung, Edward Tam, Karen Doucette, Alexander Wong, Alnoor Ramji, Brian Conway, Curtis Cooper, Keith Tsoi, Philip Wong, Giada Sebastiani, Mayur Brahmania, Sarah Haylock‐Jacobs, Carla S. Coffin, Bettina E. Hansen, Harry L.A. Janssen	18
13	Expression of Inhibitory Receptors on T and NK Cells Defines Immunological Phenotypes of HCV Patients with Advanced Liver Fibrosis 2020 ·iScience ·(unknown), Jun Oh, Angela M. Crawley, Curtis Cooper, Seung‐Hwan Lee	15
14	Gastrointestinal Symptom Distress is Associated With Worse Mental and Physical Health-Related Quality of Life 2017 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·(unknown), Janet Raboud, Jill Tinmouth, Sean B. Rourke, Sergio Rueda, Trevor Hart, Curtis Cooper, Anita Rachlis, Ann N. Burchell, (unknown)	5
15	Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study 2017 ·BMC Infectious Diseases ·(unknown), Valérie Martel‐Laferrière, Roy Nitulescu, Joseph Cox, Curtis Cooper, Mark Tyndall, Danielle Rouleau, Sharon Walmsley, (unknown), Marina B. Klein	6
16	A Pilot, Prospective, Open-Label Simplification Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Once-Daily Lopinavir-Ritonavir Monotherapy in HIV-HCV Coinfected Patients: The MONOCO Study 2012 ·HIV Clinical Trials ·Curtis Cooper, Charles la Porte, (unknown), John S. Sampalis, (unknown), Brian Conway	4
17	Comparison of Abacavir/Lamivudine and Tenofovir/Emtricitabine Among Treatment-Naive HIV-Infected Patients Initiating Therapy 2011 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Darrell H. S. Tan, Keith Chan, Janet Raboud, Curtis Cooper, Julio Montaner, Sharon Walmsley, Robert S. Hogg, Marina B. Klein, Nimâ Machouf, Sean B. Rourke, Chris Tsoukas, Mona Loutfy	15
18	A CD4+ Cell Count <200 Cells per Cubic Millimeter at 2 Years After Initiation of Combination Antiretroviral Therapy Is Associated With Increased Mortality in HIV-Infected Individuals With Viral Suppression 2010 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Mona Loutfy, Miguel Genebat, David J. Moore, Janet Raboud, Keith Chan, Tony Antoniou, David J. Milan, (unknown), Marina B. Klein, Curtis Cooper, Nimâ Machouf, Sean B. Rourke, Anita Rachlis, Chris Tsoukas, Julio Montaner, Sharon Walmsley, Marek Smieja, Ahmed M. Bayoumi, Edward J. Mills, Robert S. Hogg	39
19	31 SAFETY AND ANTIVIRAL ACTIVITY OF THE HCV NON-NUCLEOSIDE POLYMERASE INHIBITOR VX-222 IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS 2010 ·Journal of Hepatology ·M. Rodríguez‐Torres, E. Läwitz, Barbara R. Conway, K. Kaita, Aasim Sheikh, R. Ghalib, Raúl Adrover, Curtis Cooper, (unknown), (unknown), (unknown), (unknown), John G. McHutchison	26
20	[615] MANAGEMENT OF CHRONIC HEPATITIS C IN A DIVERSE POPULATION WITH PEGINTERFERON tt-2a AND RIBAVIRIN: FINAL RESULTS OF THE CANADIAN PEGASYS EXPANDED ACCESS PROGRAM (EAP) 2007 ·Journal of Hepatology ·Marc Deschênes, Eric M. Yoshida, Kevork Peltekian, Curtis Cooper, Vincent G. Bain, Mel Krajden, Morris Sherman, (unknown), Robert Balshaw, (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact